ProKidney (NASDAQ:PROK) is a pioneer in regenerative medicine with a focus on kidney diseases. The company's main objective is to transform the treatment landscape for patients suffering from chronic kidney disease (CKD) and end-stage renal disease (ESRD) through innovative regenerative medicine therapies. ProKidney's leading project, REACT (Renal Autologous Cell Therapy), aims to delay or prevent the need for dialysis or transplantation by regenerating the patient's own kidney cells. By harnessing the body's natural healing process, ProKidney is dedicated to improving patients' quality of life and reducing the healthcare system's burden posed by kidney diseases.